Outlook Therapeutics, Inc.
NASDAQ:OTLK
1.47 (USD) • At close December 24, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Outlook Therapeutics, Inc. |
Symbool | OTLK |
Munteenheid | USD |
Prijs | 1.47 |
Beurswaarde | 34,773,732 |
Dividendpercentage | 0% |
52-weken bereik | 0.87 - 12.85 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. C. Russell Trenary III |
Website | https://www.outlooktherapeutics.com |
An error occurred while fetching data.
Over Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)